



**NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT
FIRST QUARTER OF 2019 (2019Q1)**

**Substance Abuse Epidemiology Section
Prescription Drug Overdose Prevention Program
Injury and Behavioral Epidemiology Bureau
Epidemiology and Response Division**



This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of naloxone in the community.

This report is based on calendar quarters: Q1 is January-March of the calendar year.




Data for this report were drawn from several sources:

1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico.
2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies.
3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico.
4. The NM Department of Health Syringe Services Program for data on naloxone distributed via syringe exchange sites
5. The Behavioral Health Services Division in the Human Services Department for data on naloxone distributed through Office of Substance Abuse Prevention programs.

I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures

Totals

Year and Quarter	2018Q1	2018Q4	2019Q1	Quarterly % Change 2018Q4 vs 2019Q1	Quarterly % Change 2018Q1 vs 2019Q1
Total number of controlled substance patients	253,069	230,951	234,193	1.4%	-7.5%
Number of patients receiving opioids	172,187	151,006	153,396	1.6%	-10.9%
Number of opioid prescriptions filled (excluding buprenorphine/naloxone)	356,676	321,871	323,222	0.4%	-9.4%
Number of buprenorphine/naloxone prescriptions filled	22,118	23,679	23,628	-0.2%	6.8%
Number of high dose (>=90 MME/day) opioid prescriptions excluding buprenorphine/naloxone	40,554	36,902	35,002	-5.1%	-13.7%
Total MME of opioids filled - excluding buprenorphine/naloxone	309,735,438	286,198,346	274,456,795	-4.1%	-11.4%
Total MME/prescription-day	56	56	55	-1.2%	-1.7%
Number of patients receiving benzodiazepines	89,622	83,196	82,765	-0.5%	-7.7%
Number of benzodiazepine prescriptions filled	198,390	183,983	182,677	-0.7%	-7.9%
Number of high-dose(>=40 DME/day) benzodiazepine prescriptions filled	34,888	32,131	31,522	-1.9%	-9.6%
Total DME of benzodiazepines filled	107,003,268	97,830,333	94,408,678	-3.5%	-11.8%
Total DME/patient	1,194	1,176	1,141	-3.0%	-4.5%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

MME = Morphine Milligram Equivalent; reference at http://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf

DME = Diazepam Milligram Equivalent; reference at <http://archinte.jamanetwork.com/article.aspx?articleid=217249>, 2004

I. New Mexico Prescription Monitoring Program (PMP) Measures

Number of Patients with:

Year and Quarter	2018Q1	2018Q4	2019Q1	Quarterly % Change 2018Q4 vs 2019Q1	Quarterly % Change 2018Q1 vs 2019Q1
High dose opioids (>=90 MME/day)	14,575	12,791	12,319	-3.7%	-15.5%
High dose benzodiazepines (>=40 DME/day)	15,336	13,932	13,824	-0.8%	-9.9%
Opioids >=90 days and <90% of days in past 6 months	21,145	19,099	18,479	-3.2%	-12.6%
Opioids >=90% of days in past 6 months	31,409	30,597	30,080	-1.7%	-4.2%
Benzodiazepines >=90 days and <90% of days in past 6 months	23,882	21,715	21,262	-2.1%	-11.0%
Benzodiazepines >=90% of days in past 6 months	25,358	23,986	23,619	-1.5%	-6.9%
Overlapping prescriptions of opioids from different prescribers (>=10 days total overlap)	4,087	3,641	3,374	-7.3%	-17.4%
Overlapping prescriptions of benzodiazepines from different prescribers (>=10 days total overlap)	2,543	2,257	2,097	-7.1%	-17.5%
Concurrent opioid and benzodiazepines (>=10 days overlap)	21,115	18,159	17,000	-6.4%	-19.5%
High dose opioids (>=90 MME/day) plus benzodiazepines	3,922	3,293	3,135	-4.8%	-20.1%
Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months	2,873	2,396	2,269	-5.3%	-21.0%
New Opioid Patients with at least 30 days of coverage in the past 3 months	3,651	3,180	2,803	-11.9%	-23.2%
New Benzodiazepine Patients with at least 30 days of coverage in the past 3 months	4,783	4,254	4,151	-2.4%	-13.2%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

I. New Mexico Prescription Monitoring Program (PMP) Measures


New Mexico Prescribers with at least 20 controlled substance patients:

Year and Quarter	2018Q1	2018Q4	2019Q1	Quarterly % Change 2018Q4 vs 2019Q1	Quarterly % Change 2018Q1 vs 2019Q1
Total active controlled substance prescribers	3,190	3,168	3,213	1.4%	0.7%
Prescribers with at least 50% high dose of opioid prescriptions, excluding treatment prescribers	54	67	60	-10.4%	11.1%
Prescribers with at least 50% high dose of benzodiazepine prescriptions	131	124	137	10.5%	4.6%
Prescribers with at least 25% of patients having concurrent opioids and benzodiazepines	23	11	9	-18.2%	-60.9%
Some PMP Use: Requested reports on at least 25% of patients estimated to require them	1,044	1,194	1,463	22.5%	40.1%
Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances	676	631	469	-25.7%	-30.6%
Number of Patients with PMP reports requested by practitioners	113,348	128,371	169,107	31.7%	49.2%
% of Chronic opioid users with a PMP request in the past 3 months*	64.5%	67.9%	74.7%	10.1%	15.7%
% of Chronic benzodiazepine users with a PMP request in the past 3 months*	40.5%	42.4%	51.6%	21.5%	27.4%
% of New Opioid Patients with a PMP request in the past 3 months**	15.3%	20.7%	24.9%	20.4%	62.7%
% of New Benzodiazepine Patients with a PMP request in the past 3 months**	20.5%	24.0%	29.9%	24.6%	45.9%

*Chronic users are those with at least 90 days of coverage in six months.

**New patients are those with more than 4 days of coverage in the quarter and none in the prior quarter.

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients



II. Medication Assisted Treatment (Buprenorphine/naloxone and methadone) Measures

Year and Quarter	2018Q1	2018Q4	2019Q1	Quarterly % Change 2018Q4 vs 2019Q1	Quarterly % Change 2018Q1 vs 2019Q1
Treatment (buprenorphine/naloxone) prescribers with at least 10 treatment patients	151	180	189	5.0%	25.2%
Buprenorphine/naloxone patients (>=10 days)	5,668	6,171	6,282	1.8%	10.8%
Buprenorphine/naloxone prescriptions filled	22,118	23,679	23,628	-0.2%	6.8%
Total Practitioners with DATA Waiver	555	650	698	7.4%	25.8%
Nurse Practitioners and PA's with DATA Waiver	103	145	174	20.0%	68.9%

Medicaid Methadone Treatment

Number of distinct individuals with methadone claims paid by NM Medicaid	5,066	5,322	5,541	4.1%	9.4%
Number of distinct NM Medicaid providers of methadone	11	10	12	20.0%	9.1%

Methadone Treatment Programs by Survey Date	1/2018	3/2018	8/2018	12/2018	3/2019
Number of Methadone Treatment Programs	15	16	16	16	17
Number of Methadone Treatment Patients in those Programs	5,275	5,562	6,259	6,641	6,696


DATA Waivered provider data are as of the last month of the quarter

Sources:

Buprenorphine/naloxone data: NM Prescription Monitoring Program

Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid

DATA Waivered providers: US DEA Diversion Control Division



III. Naloxone Distribution and Usage Measures

Year and Quarter	2018Q1	2018Q3	2018Q4	Quarterly % Change 2018Q3 vs 2018Q4	Quarterly % Change 2018Q1 vs 2018Q4
New Enrollments in NM State Government Naloxone Programs	1,736	1,561	1,603	2.7%	-7.7%
Total Number of NM Naloxone Doses distributed	7,838	9,423	10,087	7.0%	28.7%
Total Number of NM Reported Reversals	376	642	919	43.1%	144.4%

Year and Quarter	2018Q1	2018Q3	2018Q4	Quarterly % Change 2018Q3 vs 2018Q4	Quarterly % Change 2018Q1 vs 2018Q4
Pharmacies Presenting Medicaid Naloxone Claims	189	217	234	7.8%	23.8%
Number of Medicaid Naloxone Claims Processed	1,812	1,757	1,712	-2.6%	-5.5%

Some naloxone doses were given to organizations and may not have been distributed in that quarter.

Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once. Data on reversals are combined across several agencies and programs, and the definition of a reversal may vary.

An outpatient pharmacy could present claims in more than one quarter. The total number was obtained by counting each pharmacy once. There were 369 outpatient Pharmacies with a NM address in 2017 according to the Board of Pharmacy.

All law enforcement agencies have been contacted about naloxone training and use. The data reported reflect the number of agencies where at least some officers are carrying naloxone.

Sources: NM DOH Programs; NM HSD/BHSD Programs; NM Medicaid

